Showing 5131-5140 of 8550 results for "".
- New Study Shows Cryolipolysis Reduces Enlarged Male Breastshttps://practicaldermatology.com/news/new-study-shows-cyrolipolyis-reduces-enlarged-male-breasts/2458871/Fat-freezing provides a safe and effective non-surgical alternative for men seeking breast reduction procedures, according to a new scientific analysis. Of the men who underwent fat-freezing treatments as part of the study, 95 percent noted an improved appearance and 89 percent cited less embarra
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options
- Solta Medical Launches Clear + Brilliant pelo for Laser Hair Removalhttps://practicaldermatology.com/news/solta-medical-launches-clear-brilliant-pelo-for-laser-hair-removal/2458875/Solta Medical, a division of Valeant Pharmaceuticals North America LLC launched its Clear + Brilliant pelo™ laser for permanent hair reduction. The US launch of this device, which joins Solta Medical's aesthetic device portfolio, follows a unique partnership with German Medical
- FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-approves-humira-for-moderate-to-severe-hidradenitis-suppurativa/2458873/The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults with HS. Earlier this year, the FDA granted HUMIRA orphan drug designation for t
- Suneva Medical: Bellafill Study is Largest, Longest Post-market Clinical Evaluation of Dermal Fillerhttps://practicaldermatology.com/news/suneva-medical-bellafill-study-is-largest-longest-post-market-clinical-evaluation-of-dermal-filler/2458874/Billed as the largest and longest post-market clinical evaluation of a dermal filler, a new study reported by Suneva Medical shows high levels of patient satisfaction and favorable safety outcomes with Bellafill five-years post-treatment. With an 87 percent retention rate, the study showed that a
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev
- ASDS Survey Finds Consumers Prefer Its Membershttps://practicaldermatology.com/news/asds-survey-finds-consumers-prefer-its-members/2458882/The 2015 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings for 10 specific procedures – shows the majority of respondents in eight of 10 categories who had visited a de
- Costs, Uncertainty May Cause Consumers to Delay Cosmetic Procedures: ASDShttps://practicaldermatology.com/news/costs-uncertainty-may-cause-consumers-to-delay-cosmetic-procedures-asds/2458886/Cost, fear of suboptimal results, and uncertainty over choosing a provider are the key concerns that may deter prospective patients from receiving cosmetic treatments, new findings from the 2015 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures sh
- Modernizing Medicine Reveals Telemedicine Component for its EMRhttps://practicaldermatology.com/news/modernizing-medicine-reveals-telemedicine-component-for-its-emr/2458890/Modernizing Medicine, Inc. revealed a new t
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit